Wockhardt Share Price VS UPL Share Price: Wockhardt Pharma Ltd, a multinational healthcare and pharmaceutical company, has experienced a mixed financial performance, particularly in 2023. Despite some challenges, such as negative financial results in 2023, Wockhardt’s share price shows potential for improvement in the upcoming months, largely driven by its global footprint across 30 countries. On the other hand, UPL Ltd, a leading agrochemical company, has also faced difficulties in maintaining a positive growth trajectory in the short term. Despite its extensive presence in the agrochemical industry, UPL’s stock price has been volatile in recent months, as the company grapples with market challenges.
Wockhardt Share Price VS UPL Share Price
Investors are closely monitoring the company’s upcoming results, as Wockhardt has managed to stay competitive in the pharmaceutical sector. The stock price could see steady growth, with short-term targets possibly hovering around ₹450–₹500 in 2024, while long-term projections for 2025 could push its price closer to ₹600 or higher, depending on the recovery and growth in its global markets and new drug approvals.
However, the agricultural sector’s importance and UPL’s broad product portfolio give it strong growth potential. In the short term, UPL’s share price could stabilize around ₹750–₹800, while its long-term growth prospects for 2025 and beyond could lead to a target price of ₹950–₹1,100, depending on the market recovery and demand for agrochemical products.
Wockhardt Share Price VS UPL Share Price Today Prediction
Wockhardt Pharma Ltd has seen a recent downturn, with its share price down by 3.94% as of the latest trading session. The stock, which opened at ₹578 per share, has been in a downward trajectory since reaching a high of ₹620 in early March 2024. Despite this decline, Wockhardt remains a significant player in the pharmaceutical sector, with recent developments such as a ₹400 crore fundraise via a QIP (Qualified Institutional Placement), which could provide the company with the capital to fuel growth.
On the other hand, UPL Ltd continues its struggles, with its share price falling by 0.31% to ₹494.35 after opening at ₹499.25 on the latest trading day. UPL’s stock has been on a negative trajectory for the past few years, despite the company’s strong position in the agrochemical sector. The upcoming IPO of its subsidiary, Advanta Enterprises, is expected to raise investor interest, though the company’s overall performance has been sluggish. The divestment of 10-12% by UPL could lead to some positive sentiment, but the stock remains under pressure.
Wockhardt Share Price Target From 2024 To 2030
Year | Projected Wockhardt Share Price |
2024 | ₹1,456 |
2025 | ₹2,554 |
2026 | ₹3,678 |
2027 | |
2028 | ₹5,996 |
2029 | ₹7,225 |
2030 | ₹8,345 |
Wockhardt Share Price Target 2024, 2025, 2026, 2027, 2028, 2029 To 2030
Wockhardt Share Price Target From 2024 ₹1,456, 2025 ₹2,554, 2026 ₹3,678, 2027 ₹4,875, 2028 ₹5,996, 2029 ₹7,225 To 2030 ₹8,345 Full Information
UPL Share Price Target 2024 To 2030 Forecast
Year | Maximum Target | Minimum Target |
2024 | Rs 634.09 | |
2025 | Rs 816.67 | Rs 522.80 |
2026 | Rs 970.90 | Rs 536.99 |
2027 | Rs 1,025.60 | Rs 565.09 |
2028 | Rs 1,177.00 | Rs 606.12 |
2029 | Rs 1,340.00 | Rs 655.67 |
2030 | Rs 1,527.12 | Rs 700.90 |
UPL Share Price Target 2024, 2025, 2026, 2027, 2028, 2029, To 2030
UPL Share Price Target 2024 Rs 438.54, 2025 Rs 522.80, 2026 Rs 536.99, 2027 Rs 565.09, 2028 Rs 606.12, 2029 Rs 655.67, To 2030 Rs 700.90. Full Information
Wockhardt Pharma Ltd 2024-2030
Over the next few years, Wockhardt’s stock price could experience significant fluctuations as it navigates a series of challenges and growth opportunities. The company’s strategic focus on expanding its antibiotic pipeline and vaccine production capabilities in collaboration with Serum Life Sciences could provide upside potential. Additionally, the ₹400 crore capital raise through a QIP in 2024 could strengthen its financial position and support future growth initiatives. While recent performance has been negative, with the stock down by 3.94% as of early 2024, the company’s long-term prospects could benefit from these strategic initiatives. Investors will need to watch for execution of these plans, and if successful, Wockhardt could see a recovery, possibly reaching ₹650–₹750 per share by 2030, with steady growth in the healthcare sector.
UPL Ltd 2024-2030
UPL has been on a negative stock price trajectory in recent years, with its share price remaining under pressure due to sluggish market conditions and operational challenges. However, the upcoming IPO of its subsidiary Advanta Enterprises in FY2025 could provide a short-term boost and improve investor sentiment. Despite these positive developments, UPL will face significant hurdles in regaining a strong growth trajectory, especially in the competitive agrochemical industry. If the company successfully capitalizes on its global footprint and new product lines, it could stabilize and potentially see modest growth over the next decade. However, its stock price might remain volatile in the short term, possibly fluctuating in the range of ₹475–₹550 per share by 2030, with only gradual improvements over time.
Conclusion
Both Wockhardt and UPL face challenges in 2024, but their recovery potential over the next decade will be shaped by their respective strategies. Wockhardt’s future appears more promising with its focus on pharmaceuticals and collaborations, while UPL may take longer to see substantial recovery due to the nature of the agrochemical sector. Investors will need to weigh the risks and monitor the companies’ performance closely in the coming years.
